Articles from Tune Therapeutics

Tune Therapeutics, a leading epigenome editing company, presented new data today at the European Association for the Study of Liver (EASL) Congress in Barcelona, Spain, demonstrating the first clinical evidence of epigenetic silencing in hepatitis B virus (HBV).

As momentum builds around next-generation approaches to treat chronic hepatitis B (HBV), Tune Therapeutics, a leading epigenome editing company, will spotlight new clinical data at the European Association for the Study of the Liver (EASL) Congress 2026 that underscore the promise of its approach and potential to unlock a finite therapy. At the meeting, Dr. Ed Gane, Professor of Medicine at the University of Auckland and a globally recognized authority on HBV, will present late-breaking Phase 1b/2a results for the company’s lead program, TUNE-401, a first-in-class epigenetic silencer designed to achieve deep and durable antiviral activity.

Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John McHutchison AO, MD will be its new CEO and Chairman of the Board.

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation.

Leading epigenetic therapy company Tune Therapeutics announced today that it will begin a clinical trial in Hong Kong after receiving a Certificate for Clinical Trial from the Hong Kong Department of Health. This marks the second global approval to commence a Phase 1b clinical trial for Tune-401, an investigational epigenetic silencing therapy designed to treat chronic hepatitis B (CHB).

Leading epigenome editing company Tune Therapeutics showcased new data yesterday at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV).

Leading epigenome editing company Tune Therapeutics announced today that it has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) to initiate a Phase 1b clinical trial for TUNE-401 – an investigational epigenetic silencing therapy designed to treat chronic Hepatitis B (HBV).

Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.

Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection.

Last week, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), leading epigenetic editing company Tune Therapeutics showcased the power and potential of its TEMPO TM genetic tuning platform, by presenting data showing the stable repression of the PCSK9 gene and the effective reduction of LDL-cholesterol levels in non-human primates (NHPs). This data marks a significant waypoint on the path to epigenetic medicine, in that it represents the first demonstration of durable epigenetic gene regulation, in a large animal model, following transient delivery of an epi-editor.

Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, Ph.D., and General Counsel, Zachary Hale, J.D.

Tune Therapeutics, a biotechnology company pioneering the creation of genetic tuning (epigenomic editing) therapies, today announced the addition of John McHutchison AO, MD – former CEO at Assembly Biosciences, Inc., and CSO at Gilead Sciences, Inc. – to its board of directors. Dr. McHutchison joins as a noted industry leader with extensive experience in advancing novel treatments for the benefit of patients facing serious, intractable diseases.